The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis.
about
Cardiovascular risk assessment in rheumatoid arthritis - controversies and the new approachCardiovascular risk in rheumatoid arthritis: assessment, management and next stepsImpact of tofacitinib on patient outcomes in rheumatoid arthritis - review of clinical studiesMaking the next steps in psoriatic arthritis management: current status and future directionsManaging cardiovascular risk in patients with inflammatory arthritis: practical considerationsPsoriasis and comorbid diseases: Implications for management.Management of cardiovascular disease in patients with psoriasis.Cardiovascular Comorbidity in Inflammatory Rheumatological Conditions.Anti-TNF-alpha agents and endothelial function in rheumatoid arthritis: a systematic review and meta-analysisPsoriasis and Cardiovascular Risk: Strength in Numbers Part 3The challenging interplay between rheumatoid arthritis, ageing and comorbidities.Therapeutic potential of folic acid supplementation for cardiovascular disease prevention through homocysteine lowering and blockade in rheumatoid arthritis patients.Inflammation as a Risk of Developing Chronic Kidney Disease in Rheumatoid Arthritis.Strategies, models and biomarkers in experimental non-alcoholic fatty liver disease researchChallenges of developing a cardiovascular risk calculator for patients with rheumatoid arthritis.Decreased use of glucocorticoids in biological-experienced patients with rheumatoid arthritis who initiated intravenous abatacept: results from the 2-year ACTION study.Improving cardiovascular health and metabolic comorbidities in patients with psoriatic arthritisUnexpected arterial wall and cellular inflammation in patients with rheumatoid arthritis in remission using biological therapy: a cross-sectional study.Serum Resistin Level and Progression of Atherosclerosis during Glucocorticoid Therapy for Systemic Autoimmune DiseasesUpdates on Psoriasis and Cutaneous Oncology: Proceedings from the 2016 MauiDerm Meeting based on presentations by.Psoriasis comorbidities: complications and benefits of immunobiological treatmentPatterns of Cardiovascular Mortality for HIV-Infected Adults in the United States: 1999 to 2013Effect of IL-6 receptor blockade on high-sensitivity troponin T and NT-proBNP in rheumatoid arthritis.Cardiovascular comorbidity in rheumatic diseases.Prevention of Stroke in Rheumatoid Arthritis.Unmet Needs in the Pathogenesis and Treatment of Cardiovascular Comorbidities in Chronic Inflammatory Diseases.Cardiac involvement in primary systemic vasculitis and potential drug therapies to reduce cardiovascular risk.Coronary microvascular dysfunction in chronic inflammatory rheumatoid diseases.Rheumatoid Arthritis Pharmacotherapies: Do They Have Anti-Atherosclerotic Activity?Targeting inflammation to reduce cardiovascular disease risk: a realistic clinical prospect?Immune-mediated mechanisms of atherosclerosis and implications for the clinic.Biologic drugs and arrhythmic risk in chronic inflammatory arthritis: the good and the bad.Cardiovascular Safety of Tocilizumab Versus Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis: A Multi-Database Cohort Study.Factors Associated With Sustained Remission in Rheumatoid Arthritis in Patients Treated With Anti-Tumor Necrosis Factor.Impact of non-steroidal anti-inflammatory drugs on cardiovascular risk: Is it the same in osteoarthritis and rheumatoid arthritis?Management of Cardiovascular Risk in Patients with Chronic Inflammatory Diseases: Current Evidence and Future Perspectives.The therapeutic potential of plant flavonoids on rheumatoid arthritis.Angiopoietin-like 4: A molecular link between insulin resistance and rheumatoid arthritis.Anti-inflammatory drugs as promising cardiovascular treatments.The effect of rheumatoid arthritis-associated autoantibodies on the incidence of cardiovascular events in a large inception cohort of early inflammatory arthritis.
P2860
Q26738461-59348726-47ED-4F3C-B3F5-80D7E5862447Q26744334-0C9C227E-10CF-4E6D-BE75-7A84BABB8747Q26772850-DF51890D-2487-4C63-A9A3-A86C77795315Q26783506-7A7FC42A-744A-461B-A92E-4987F11C2AB0Q27694518-1ADDBF94-4AB6-4FA1-8FA2-E2318F1976B2Q30235888-3C59672B-55C5-451E-BBF1-B277B615B306Q30250278-AD60EAA6-D02B-4883-B589-18DAD1ED562BQ33582869-E5A9A15E-3394-48E5-9B77-AC119ED2E433Q33902895-5237F555-3240-4714-A332-798AFF78E8A5Q35962417-3E008861-0C7E-40EB-88F2-0466AAC25B9AQ36000249-4D146ECA-DE6C-4622-AA17-4EFD8FD08611Q36027291-BB6A0B66-86C6-4F81-B7FF-C7F96A899894Q36106803-7534F04C-3FDA-4607-B016-B661E4828C37Q36129673-FD43682D-271E-4423-8763-2CA0F49988BAQ36320021-36BC7007-B78A-45E9-8D9E-1096AD0BF7A8Q36603266-C8FF9291-942F-4D82-ABAB-27A988F54CA2Q36843650-D291CAED-809D-49A1-A4DE-61602926E81DQ36923331-68E953E4-9609-4A5D-A688-A0E74ED4DD73Q37294162-300D7079-146A-4784-AC6B-53647D34EBFFQ37362082-085211C8-DF2E-4815-99F5-79D31FBA609BQ37540440-883A8AAD-F38F-4100-BA89-13430208973AQ37641013-E4E95DDA-EA01-47E6-B1FB-8F9526D18032Q38386565-73DD7657-9B1E-4C55-8BFF-2A623CD624CBQ38568465-9AB002D5-E186-461B-90F6-1431FC7EE7C6Q38612651-54ABE530-C409-4827-A9CD-04665942A920Q38663003-E41AE2EB-F869-4D17-8905-CABBC7F20FACQ38737288-8D08E923-43DA-4B53-911F-1C617064617DQ38749160-51C30D05-9283-4324-A8E0-352062223687Q38794852-6B479A16-857D-4E75-AD16-8F7B97ED4C76Q38836998-6B3B0520-F4E8-4F5F-8765-B8834B47D0C5Q38851472-85C6144D-6B9E-4B3A-8B0F-11BD85A3F5EFQ38898838-5AAE0434-74AB-44A4-BCEB-1603B9305A47Q38937245-023665FA-D840-4444-87EB-DB61C6FE6300Q38937827-D689E031-2FA3-4B6B-93B9-C9FF70BEDDB5Q38962092-10509A76-235B-4FA9-A060-BECFB583A722Q38972344-5A0E4346-0BFE-4C95-972B-FCA491763C42Q39016582-BF42EB47-E9B0-47C6-88A3-AB80160BAC32Q39048436-E7F0A900-A41B-4343-945A-B70E8DBC173CQ39051784-6A396E09-1427-483E-9BCD-7F32F9C39D65Q39078542-15AED503-4E5C-4DFA-826B-05EB7E456C42
P2860
The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis.
description
2015 nî lūn-bûn
@nan
2015 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի մարտին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
The effects of tumour necrosis ...... atic review and meta-analysis.
@ast
The effects of tumour necrosis ...... atic review and meta-analysis.
@en
type
label
The effects of tumour necrosis ...... atic review and meta-analysis.
@ast
The effects of tumour necrosis ...... atic review and meta-analysis.
@en
prefLabel
The effects of tumour necrosis ...... atic review and meta-analysis.
@ast
The effects of tumour necrosis ...... atic review and meta-analysis.
@en
P2093
P2860
P921
P1476
The effects of tumour necrosis ...... matic review and meta-analysis
@en
P2093
Alexandra McFarlane
Boulos Haraoui
Camille Roubille
Charles Lynde
Collette McCourt
John Kraft
Louis Bessette
Patrick Fleming
Robert Bissonnette
P2860
P304
P356
10.1136/ANNRHEUMDIS-2014-206624
P407
P50
P5008
P577
2015-01-05T00:00:00Z